A number of minor compounds were isolated from fermentations of the protorifamycin I producing strain Nocardia mediterranei F 1,/241,2) and identified by means of chemical and spectroscopic methods. Two types of structures were identified:
As described earlier1), protorifamycin I, the main product of Nocardia mediterranei F 1/24 is the earliest precursor for the ansamycins of the rifamycin-type isolated so far. Two minor compounds of the ansamycin-complex from mutant F 1/24 were identified as protorifamycin I-Ml2) (degradation product of protorifamycin I) and proansamycin B-Ml2) (degradation product of proansamycin B, the common progenitor for the naphthalenic ansamycins postulated in part I of this series of papers1). Protorifamycin I-MI and proansamycin B-Ml are the first reported ansamycins with an opened ansa chain.* In this final paper we describe nine further products of Nocardia mediterranei F 1/24 which we were able to identify (structures Fig. 1 ). Six of these minor compounds are direct modifications of protorifamycin I (type 1), namely: protorifamycin I-lactone, 23-ketoprotorifamycin I, 30-hydroxyprotorifamycin I, 20-hydroxyprotorifamycin I, 13-hydroxyprotorifamycin I and 23-acetoxyprotorifamycin I. Three of the identified minor compounds are defective rifamycins (type 2), namely: 8-deoxyrifamycin B, 8-deoxyrifamycin S (SV) and 8-deoxy-3-hydroxyrifamycin S (SV).
Experiments and Results

Fermentation, Isolation and Purification of the Minor Ansamycins
To obtain large enough amounts of the minor compounds from Nocardia mediterranei F 1/24 a fermentation was carried out in a 30-liter fermenter with liquid complex medium 151b as described in the preceding paper2). This fermentation yielded 78 g of crude ansamycin mixture after extraction.2) By repeated chromatography on silica-gel columns using chloroform-methanol-and toluol-ethyl acetatemethanol-gradients the ansamycin-compounds were separated and enriched. Final purification was achieved by preparative TLC on silica-gel PF 254 plates (1.5 mm layer, Merck).
The following amounts of chromatographically pure ansamycins were obtained: protorifamycin I (16.9 g), proansamycin B-Ml2) (190 mg), protorifamycin I-Ml2) (60 mg), protorifamycin I-lactone (970 mg), 23-ketoprotorifamycin I (247 mg), 30-hydroxyprotorifamycin I (180 mg), 20-hydroxyprotorifamycin I (125 mg), 13- C (2) C (3) C (4) C (5) C (6) C (7) c (8) C (9) c (10) c (11) C (12) C (15) C (16) C (17) C ( The 13C-NMR spectra of 13-hydroxyprotorifamycin I, 30-hydroxyprotorifamycin I and 3-deoxvrifamycin B were only of minor quality, but the most important signals could be assigned. Table   2 .
360-MHz NMR data of the 8-deoxyansamycins from mutant F 1/24.
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0.85d (6) I .07d (6) 0.57d 0. 80d (7) 1.00d (7) 0. 6d (7) ~0 .1d* 0.82d (7) I.0d (7) 0. 62d (7) ~0 .1d* By this comparison most of the carbons in the 13C-NMR spectra as well as most of the protons in the 1H-NMR spectra could be assigned (see Tables 1 and 2 ). In the 1H-NMR spectra of the 8-deoxyrifamycins of the protorifamycin I-type (type 1) the aromatic proton H-8 was normally found at 7.9 ppm.
The structures of the new 8-deoxyansamycins are discussed in detail below.
Protorifamycin I-lactone (C35H41NO10, M+ at m/e 635)
In protorifamycin I-lactone the C-34a hydroxymethyl group of protorifamycin I at C-28 is oxidized to a carboxylic group which forms a lactone with the C-25 hydroxyl group. The 13C-NMR spectrum is in good agreement with the postulated structure.
The signal of C-34a found at 64.3 ppm in protorifamycin I has shifted downfield to 174.4 ppm corresponding there to a carbonyl signal.
In addition the signals of C-25 and C-28 shifted to lower field, too, whereas for C-29 a small upfield shift was observed.
In the 360 MHz-NMR spectrum of the lactone the proton H-28 was found at 3.5 ppm (doublet), whereas the AB-system of the H-34a protons is missing. The coupling of H-28 with the olefinic proton H-29 at 6.12 ppm was demonstrated by a decoupling experiment.
In addition the exact positions of the protons H-20 to H-27 were confirmed by double resonance experiments.
23-Ketoprotorifamycin I (C35H43NO10, M+ of the persilylated product at rn/e 1071 corresponding to a molecular weight of 637).
The structure assignment of 23-ketoprotorifamycin I is based on the following observations:
In the 13C-NMR spectrum only four signals of C-atoms beside oxygen are present: C-21, C-25, C-27 and C-34a.
The signal of C-23 found at 74 ppm in protorifamycin I has shifted downfield to 220.8 ppm corresponding there to a ketogroup.
In the 360 MHz-NMR spectrum the signal of the H-23 proton is missing, whereas the proton H-21 was localized as a double doublet at 3.40 ppm. Therefore a ketogroup at C-21 can be excluded.
In 
30-Hydroxyprotorifamycin I (C35H91NO11, FD-MS: M+ at m/e 655)
The structure differs from protorifamycin I only by its primary hydroxyl group at C-30 as evidenced by lacking the signal of the C-30 vinylic methyl group found at 20.2 ppm in the 13C-NMR spectrum of protorifamycin I. In the 360 MHz-NMR spectrum only one vinylic methyl group is present (2.1 ppm).
Its long range coupling with the olefinic proton H-29 could be demonstrated by a decoupling experiment.
Therefore the remaining vinylic methyl group has to be the C-13 one. On the other hand a new ABsystem at 4.30 ppm can be attributed to the C-30 hydroxymethyl group.
20-Hydroxyprotorifamycin I (C35H41NO11, FD-MS: M+ at m/e 655)
The structure assignment of 20-hydroxyprotorifamycin I is based on the fact that in the 13C-NMR spectrum the C-20 signal found at 39 ppm in protorifamycin I is missing, whereas C-22, C-24, C-26 and C-28 show their normal chemical shifts.
On the other hand due to the hydroxyl group at C-20 an additional signal was localized at 75.9 ppm. In addition small downfield shifts were observed for the C-31 Spectra were carried out with the oxidized form. In the 360 MHz-NMR spectrum the signal of the H-3 proton has disappeared, whereas the H-8 proton is still present at 8.16 ppm. The rest of the 1H-NMR spectrum is almost identical with that of rifamycin S. From the molecular weight which is 16 mass units higher than for 8-deoxyrifamycin S it was concluded that C-3 is substituted by an additional hydroxyl group. The postulated structure was supported by the 13C-NMR spectrum. Compared to 8-deoxyrifamycin S or rifamycin S strong shift differences were observed for the aromatic carbons C-2, C-3 and C-4 due to the hydroxyl group in position 3. With these findings the structure of 8-deoxy-3-hydroxyrifamycin S seems to be well established.
Biological Activity
The 8-deoxyansanrycins isolated from Nocardia mediterranei F 1/24 showed no or very weak activity against Gram-positive bacteria, Gram-negative bacteria and Candida albicans.
For the products of type 1 this is not surprising because rifamycin W was found to be inactive, too. In the case of rifamycin W it was assumed that the lack of activity is due to an unsuitable spatial relationship between the hydroxyls at C-8, C-21 and C-23.6) By investigating chemical derivatives of rifamycin S (SV), tolypomycin Y, streptovaricin C and rifampicin it was found that the oxygens at C-1 and C-8 (as hydroxyls or as quinoid oxygen) and the two hydroxyls at C-21 and C-23 must be involved in the formation of the complex between the active ansamycin and the bacterial RNA-polymerase7-9). Derivatization at C-8 (e.g. acetylation) yields inactive products7-9). The isolation of the inactive 8-deoxyansamycins of type 2, especially of 8-deoxyrifamycin S and 8-deoxy-3-hydroxyrifamycin S is a direct proof that the oxygen function at C-8 is essential for the biological activity of the naphthalenic ansamycins and does fully confirm the data from analyzing derivatives.
Discussion
The structures of the compounds isolated from Nocardia mediterranei F 1/24 supply us with considerable biosynthetic information.
1. Protorifamycin I, the earliest direct precursor for the ansamycins of the rifamycin-type, is struc- Similar modifications are known for some end-products of the rifamycin group.
Hydroxylation at C-20 or C-30 has been found before in rifamycin Y11) or rifamycin R'2 , respectively, whereas the hydroxylation at C-13 and the acetylation of the C-23 hydroxyl group has never been detected so far. However, most of the active rifamycins e.g. S, SV and B bear an acetoxy group at C-25. All these rifamycin-data together with the information from the indicates that the elimination of C-34a during the transformation: protorifamycin I->8-deoxyrifamycin S (or rifamycin W--*rifamycin S) follows the normal route for elimination of methyl by decarboxylation:
The formation of protorifamycin I-lactone together with 8-deoxyrifamycin S, 8-deoxy-3-hydroxyrifamycin S and 8-deoxyrifamycin B proves that the enzyme systems for the elimination of C-34a, for the ring extention (introduction of oxygen between C-12 and C-29), for the formation of the fivemembered ring in the chromophore and for the transformation: 8-deoxyrifamycin S-8-deoxyrifamycin B (or rifamycin S-*rifamycin B) accept both the 8-deoxy-and the 8-hydroxy-products as substrates. Protorifamycin I, however, is not as good as substrate as rifamycin W and the transformation protorifamycin I-8-deoxyrifamycin B is very slow. In Nocardia mediterranei F 1/24 only a small part (approximately 10%) of the synthesized protorifamycin I is transformed into protorifamycin I-lactone, 8-deoxyrifamycin S, 8-deoxy-3-hydroxyrifamycin S and 8-deoxyrifamycin B during the fermentation; the rest is accumulated in the culture broth (or modified by hydroxylation etc. to approx. 5%), in contrast to the original strain N813 (rifamycin B producer) where the transformation: rifamycin W-->rifa-mycin B is almost complete and no significant accumulation of precursors such as the corresponding rifamycin W13) can be observed.
In the streptovaricin-producing organism Streptomyces spectabilis all these enzyme systems mentioned above seem to be absent (or non-functional) because all the known ansamycins of the streptovaricin-type bear an unmodified C-28 methyl group C-34a, have an uncleaved carbon ansa chain with no oxygen between C-12 and C-29, no five-membered ring in the chromophore and no glycolic acid at C-410.14)
6. In the case of 8-deoxy-3-hydroxyrifamycin S different biogenetic origins can be postulated: C-3 hydroxylation of 8-deoxyrifamycin S. C-3 hydroxylation of a precursor such as protorifamycin I or proansamycin B followed by transformation into 8-deoxy-3-hydroxyrifamycin S.
Ansamycin biosynthesis beginning with a seven-carbon amino starter unit different from that for the normal rifamycins and streptovaricins (starter unit hydroxylated in the position which later becomes position 3 of the final ansamycins) 15.16) .
With the present knowledge we can not decide which of these possible pathways is correct.
